The Clinician Interview-Based Impression (CIBI): A clinician’s global change rating scale in Alzheimer’s disease

Neurology

Volumn 44, Issue 12, 1994, Pages 2315-2321

  Knopman, David S ^a   Knapp, Margaret J ^b   Gracon, Stephen I ^b   Davis, Charles S ^c  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELIABILITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CLINICAL TRIALS; COGNITION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERVIEWS; MALE; MIDDLE AGED; PLACEBOS; PRACTICE GUIDELINES; TACRINE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0028114429     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.44.12.2315     Document Type: Article

References (40)

1. Leber P. Guidelines for the clinical evaluation of antidementia drugs. Letter to the Warner-Lambert Co., November 8, [Letter available on request from Knopman et al.]
2. Beneke M, Rasmus W. “Clinical Global Impressions” (ECDEU): some critical comments. Pharmacopsychiatry 1992;25:171-176.
3. Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: US Department of Health Education and Welfare, 1976:218-220.
4. Davis KL, Thai LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. N Engl J Med 1992;327:1253-1259.
5. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer’s disease. JAMA 1992;268:2523-2529.
6. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994;271:985-991.
7. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939-944.
8. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356-1364.
9. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
10. DeJong R, Osterlund OW, Roy GW. Measurement of quality of life changes in patients with Alzheimer’s disease. Clin Ther 1989;11:545-554.
11. Reisberg B, Ferris SH, deLeon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-1139.
12. Leber P. Letter to the Warner-Lambert Co., November 1, [Letter available on request from Knopman et al.]
13. Katzman R, Brown T, Fuld P, Peck A, Schecter R, Schimmel H. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry 1983;140:734-739.
14. Kramer MS, Feinstein AR. Clinical biostatistics. LIV. The biostatistics of concordance. Clin Pharmacol Ther 1981;29:111-123.
15. Dahlke F, Lohaus A, Gutzmann H. Reliability and clinical concepts underlying global judgments in dementia: implications for clinical research. Psychopharmacol Bull 1992;28:425-432.
16. Knopman D, Gracon S. Observations on the short-term ‘natural history’ of probable Alzheimer’s disease in a controlled clinical trial. Neurology 1994;44:260-265.
17. Gaitz CM, Varner RV, Overall JE. Pharmacotherapy for organic brain syndrome in late life: evaluation of an ergot derivative versus placebo. Arch Gen Psychiatry 1977;34:839-845.
18. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987;40:171-178.
19. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol 1990;27:457-464.
20. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer’s disease: synaptic loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-580.
21. Neary D, Snowden JS, Mann DMA, et al. Alzheimer’s disease: a correlative study. J Neurol Neurosurg Psychiatry 1986;49:229-237.
22. DeKosky ST, Harbaugh RE, Schmitt FA, et al. Cortical biopsy in Alzheimer’s disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive impairment. Ann Neurol 1992;32:625-632.
23. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2:1457-1459.
24. Morris JC, Edland S, Clark C, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer’s disease. Neurology 1993;43:2457-2465.
25. Galasko D, Corey-Bloom J, Thai LJ. Monitoring progression in Alzheimer’s disease. J Am Geriatr Soc 1991;39:932-941.
26. Mortimer JA, Ebbitt B, Jun S-P, Finch MD. Predictors of cognitive and functional progression in patients with probable Alzheimer’s disease. Neurology 1992;42:1689-1696.
27. Reed BR, Jagust WJ, Seab JP. Mental status as a predictor of daily function in progressive dementia. Gerontologist 1989;29:804-807.
28. Stern Y, Hesdorffer D, Sano M, Mayeux R. Measurement and prediction of functional capacity in Alzheimer’s disease. Neurology 1990;40:8-14.
29. van Belle G, Uhlmann RF, Hughes JP, Larson EB. Reliability of estimates of changes in mental status test performance in senile dementia of the Alzheimer type. J Clin Epidemiol 1990;43:589-595.
30. Weiler PG, Chiriboga DA, Black SA. Comparison of mental status tests: implications for Alzheimer’s patients and their caregivers. J Gerontol 1994;49:S44-S51.
31. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
32. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
33. Roth M, Tym E, Mountjoy CQ, et al. CAMDEX: a standardized instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986;149:698-709.
34. Burke WJ, Miller JP, Rubin EH, et al. Reliability of the Washington University Clinical Dementia Rating. Arch Neurol 1988;45:31-32.
35. Gottlieb GL, Gur RE, Gur RC. Reliability of psychiatric scales in patients with dementia of the Alzheimer type. Am J Psychiatry 1988;145:857-860.
36. Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G. Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol 1992;31:242-249.
37. Eisdorfer C, Cohen D, Paveza GJ, et al. An empirical evaluation of the global deterioration scale for staging Alzheimer’s disease. Am J Psychiatry 1992;149:190-194.
38. Salmon DP, Thai LJ, Butters N, Heindel WC. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology 1990;40:1225-1230.
39. Berg G, Edwards DF, Danzinger WL, Berg L. Longitudinal changes in three brief assessments of SDAT. J Am Geriatr Soc 1987;35:205-211.
40. Thai LJ, Grundman M, Golden R. Alzheimer’s disease: a correlational analysis of the Blessed information-memory-con- centration test and the mini-mental state exam. Neurology 1986;36:262-264.